8-K: Checkpoint Therapeutics Announces Full-Year 2024 Financial Results and Merger Agreement with Sun Pharma

Checkpoint Therapeutics reports its full-year 2024 financial results, highlighted by the FDA approval of UNLOXCYT and a pending merger agreement with Sun Pharmaceutical Industries.

Summary

• Checkpoint Therapeutics announced its full-year 2024 financial results and recent corporate updates on March 28, 2025.
• The company entered into a merger agreement with Sun Pharmaceutical Industries, with Checkpoint continuing as a wholly-owned subsidiary of Sun Pharma; the total transaction value is up to approximately $416 million, expected to close in the second quarter of 2025.
• In December 2024, the FDA approved UNLOXCYT (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).
• Longer-term data from the pivotal trial of cosibelimab in cSCC were presented at the ESMO Congress in September 2024, demonstrating a deepening of response over time.
• As of December 31, 2024, Checkpoint's cash and cash equivalents totaled $6.6 million, compared to $4.9 million at December 31, 2023.
• Subsequent to the fiscal year-end, Checkpoint received approximately $38.1 million in cash proceeds from warrant exercises.
• Research and development expenses for 2024 were $36.2 million, compared to $43.6 million in 2023.
• General and administrative expenses for 2024 were $20.1 million, compared to $8.7 million in 2023.
• The net loss attributable to common stockholders for 2024 was $56.2 million, or $1.42 per share, compared to a net loss of $51.8 million, or $3.17 per share, for 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The FDA approval of UNLOXCYT and the merger agreement with Sun Pharma are positive developments. However, the increased net loss and G&A expenses temper the overall sentiment.

Positives

• The FDA approval of UNLOXCYT provides a significant commercial opportunity for Checkpoint Therapeutics.
• The merger agreement with Sun Pharma provides substantial value to Checkpoint's shareholders.
• The company received $38.1 million in cash proceeds from warrant exercises after the fiscal year-end, strengthening its financial position.
• Longer-term data from the pivotal trial of cosibelimab presented at ESMO showed a deepening of response over time.

Negatives

• The company reported a net loss of $56.2 million for the year ended December 31, 2024.
• General and administrative expenses increased significantly from $8.7 million in 2023 to $20.1 million in 2024.
• The company's cash position was $6.6 million as of December 31, 2024, which may require additional financing if the merger is not completed in a timely manner.

Risks

• The merger with Sun Pharma is subject to customary closing conditions, including regulatory approvals and stockholder approval, and may not be completed.
• The company's future performance depends on the successful commercialization of UNLOXCYT.
• The company faces risks related to the non-achievement of the CVR milestone in the merger agreement.
• The company is exposed to risks related to product liability and legal proceedings.

Future Outlook

The company anticipates the merger with Sun Pharma to be completed in the second quarter of 2025 and will focus on the commercial launch and availability of UNLOXCYT for the treatment of adults with metastatic or locally advanced cSCC.

Industry Context

The approval of UNLOXCYT positions Checkpoint Therapeutics as a key player in the immunotherapy space, specifically in the treatment of cutaneous squamous cell carcinoma. The merger with Sun Pharma could provide the resources and infrastructure needed to maximize the commercial potential of UNLOXCYT.

Comparison to Industry Standards

• Checkpoint's UNLOXCYT is the first and only PD-L1 blocking antibody approved for cSCC, giving it a competitive advantage over other treatments.
• Competitors in the cSCC treatment space include companies like Regeneron and Sanofi with their PD-1 inhibitor Libtayo, but UNLOXCYT's PD-L1 specificity offers a differentiated approach.
• The $416 million merger valuation is comparable to other acquisitions in the oncology space, reflecting the potential value of Checkpoint's pipeline and approved product.

Related Party Transactions

• Revenue from related party was $41,000 in 2024 compared to $103,000 in 2023.
• Accounts payable and accrued expenses related party was $2,433,000 as of December 31, 2024, compared to $2,815,000 as of December 31, 2023.

Stakeholder Impact

• Shareholders will benefit from the merger agreement with Sun Pharma.
• Patients with metastatic or locally advanced cSCC will have access to a new treatment option with UNLOXCYT.
• Employees may experience changes as a result of the merger.

Next Steps

• Complete the merger with Sun Pharmaceutical Industries in the second quarter of 2025.
• Focus on the commercial launch and availability of UNLOXCYT.
• Continue evaluating olafertinib as a potential treatment for EGFR mutation-positive non-small cell lung cancer.

Key Dates

Keywords

Checkpoint Therapeutics, Sun Pharma, Merger, UNLOXCYT, Cosibelimab, FDA Approval, Financial Results, cSCC, Oncology, Immunotherapy